Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Good question. Probably the easy answer is back then there was just no call for it. For what I gather Leo paid for this payer analysis so likely insurance reimbursements came up during discussions since B is a new drug for insurance to consider.
My opinion is payer analysis was likely driven by talks with an interested party as part of their current negotiations. If approved B-OM may be considered a new Tier4 drug but since there is no substitute in the fact that OM is a unmet need Insurance would pay for it. It was reported here I think that Leo had a new business development hire. We wait and see.